PATENT CLAIM ANALYSIS

Application Number: 16257581
Application Type: Utility
Filing Date: 2019-01
Publication Date: 2019-08
Patent Classification: ["514", "293000"]

Abstract:
Disclosed are methods and pharmaceutical compositions for treating a cancer in a subject in need thereof, the cancer characterized by proteolytic cleavage by taspase1 of the mixed-lineage leukemia 1 gene product (MLL1), the method comprising administering to the subject a therapeutic agent that inhibits cleavage by taspase1 of MLL1. Suitable therapeutic agents may include agents that inhibit the kinase activity of casein kinase II (CKII). Cancer treated by the disclosed methods and pharmaceutical compositions may include leukemia such as Acute Lymphoblastic Leukemia (ALL) and/or Acute Myeloid Leukemia (AML) and in particular, leukemia characterized by rearrangements in MLL1.

Claim (Index 11):
The method of  claim 1 , wherein the therapeutic agent comprises a compound having the following formula or a pharmaceutical salt thereof: wherein: R 3 , R 4 , R 5 , R 6 , R 7 , and R 8  are selected from hydrogen, halo, amino, cyano, hydroxyl, alkyl, alkenyl, and alkynyl; and R 9  is hydroxyl or alkoxy.

Metadata:
- Claim Count in Document: 50.0
- Percentile: 99.0
- Lexical Diversity: 1.7619
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15497783', '16030046', '15939604', '14302219', '13260540']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7703568796014575
- 35 USC 102 Novelty (BERT): 0.5488345216923246
- Combined Prediction Score: 0.7482046438105443
- Mean Citation Score: 343.1273460000001
- Max Citation Score: 403.11276
- Similarity Product: 236.52803406734705

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test